Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats.

Nakagawa T, Ukai K, Ohyama T, Koida M, Okamura H

Life sciences1 Jan 1996Cited by 7 (Europe PMC)

PMID8761023DOI10.1016/0024-3205(96)00356-6PepBankPUB-08761023

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Activity measurement
In low growth rats, plasma GH after i.v. KP-102 at 100 micrograms/kg was 1/6.7 of that in normal rats.
In plain wordsIn low growth rats, the growth hormone rise after KP-102 was much smaller than in normal rats given the same dose.
Peptide
GHRP-2
Outcome
DecreasePlasma GH after i.v. KP-102 in low growth rats versus normal rats
Study
ratn: not reported in source
Neonatally sodium-glutamate-treated low growth rats under pentobarbital anesthesia
Comparator
Normal rats given the same dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/kg · intravenousAs given in this study (rat).
Source sentences
Summary
The plasma GH level in NMSG-LG rats after i.v. administration of KP-102 at 100 micrograms/kg was 1/6.7 (95% C.L. 1/14.7 - 1/3.0) of that in normal rats given the same dose (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102301
02AnimalAnimal study (in vivo)Activity measurement
In low growth rats, the increase in plasma GH after KP-102 was still significant compared with normal rats given saline.
In plain wordsIn low growth rats, KP-102 still raised growth hormone more than saline did in normal rats.
Peptide
GHRP-2
Outcome
IncreasePlasma GH after i.v. KP-102 in low growth rats versus saline in normal rats
Study
ratn: not reported in source
Neonatally sodium-glutamate-treated low growth rats under pentobarbital anesthesia
Comparator
Normal rats given saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/kg · intravenousAs given in this study (rat).
Source sentences
Summary
However, the increase was significant compared with that in normal rats after saline administration (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The plasma GH level in NMSG-LG rats after i.v. administration of KP-102 at 100 micrograms/kg was 1/6.7 (95% C.L. 1/14.7 - 1/3.0) of that in normal rats given the same dose (p < 0.01).
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102302
03AnimalAnimal study (in vivo)Activity measurement
In rats with arcuate nucleus lesions, the GH-releasing action of i.v. KP-102 was about 1/6.3 of that in normal rats.
In plain wordsIn rats with damage to a brain area called the arcuate nucleus, KP-102 released much less growth hormone than in normal rats.
Peptide
GHRP-2
Outcome
DecreasePlasma GH after i.v. KP-102 in rats with arcuate nucleus lesions
Study
ratn: not reported in source
Rats with bilateral lesions of the hypothalamic arcuate nuclei under pentobarbital anesthesia
Comparator
Normal rats under pentobarbital anesthesia
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/kg · intravenousAs given in this study (rat).
Source sentences
Summary
The plasma GH releasing action of KP-102 at 100 micrograms/kg i.v. in rats with lesions in the bilateral hypothalamic arcuate nuclei (ARC), was about 1/6.3 (95% C.L. 1/12.4 - 1/3.2) of that in normal rats under PB anesthesia (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102303
04AnimalAnimal study (in vivo)Activity measurement
In rats, KP-102 injected into the arcuate nucleus at 0.0002, 0.02 and 2 micrograms/rat released GH in a dose-related manner.
In plain wordsIn rats, KP-102 injected into a brain area called the arcuate nucleus released growth hormone, with larger doses giving more.
Peptide
GHRP-2
Outcome
IncreaseGH release after KP-102 injected into the arcuate nucleus
Study
ratn: not reported in source
Rats under pentobarbital anesthesia
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.0002, 0.02 and 2 micrograms/rat · injection into the arcuate nucleusAs given in this study (rat).
Source sentences
Summary
When KP-102 was injected into the ARC at doses of 0.0002, 0.02 and 2 micrograms/rat, GH release was dose-related (p < 0.01) under PB anesthesia.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102304
05AnimalAnimal study (in vivo)Activity measurement
In rats, KP-102 at 2 micrograms i.c.v. increased plasma GH levels, to about 1/8.3 of the level from systemic administration.
In plain wordsIn rats, KP-102 given into the brain ventricles raised growth hormone, but less than when given through the blood.
Peptide
GHRP-2
Outcome
IncreasePlasma GH after intracerebroventricular KP-102
Study
ratn: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 micrograms · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
KP-102 at 2 micrograms i.c.v. also increased the plasma GH levels (p < 0.01) to about 1/8.3 (95% C.L. 1/22.7 - 1/3.1) of that by systematic administration, at the same potency as the ARC injection (1/13.7 and 95% C.L. 1/37.2 - 1/5.0).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102305
06AnimalAnimal study (in vivo)Mechanism
In rats, the GH-releasing action of KP-102 was similar and additive upon both regions at the maximum effective dose.
In plain wordsIn rats, KP-102 released growth hormone with similar and additive effects on both regions tested, at the highest effective dose.
Peptide
GHRP-2
Outcome
IncreaseGH-releasing action across both regions in vivo
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
maximum effective doseAs given in this study (rat).
Source sentences
Summary
Furthermore, the GH-releasing action of KP-102 was similar and additive upon both regions in vivo at the maximum effective dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats.
Report a problemFND-0876102306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.